

To: All Facilities Reimbursed Under the Hospital Outpatient Prospective Payment System (OPPS)

From: CareFirst of Maryland, Inc. – Medicare Part A

Date: March 30, 2004

Subject: Payment Rate for Fulvestrant (Faslodex) under the Hospital Outpatient Prospective Payment System (OPPS)

Section I of Transmittal 113, Claims Requiring Adjustment As a Result of April 2004 Changes to the Outpatient Prospective Payment System, Change Request (CR) 3145, dated February 27, 2004 states the changes in payment rate and copayment for Fulvestrant (Faslodex) effective January 1, 2004. The \$156.72 payment rate shown for HCPCS code J9395, Injection, Fulvestrant, 25 mg, is incorrect. The **correct payment rate** for HCPCS code J9395, Injection, Fulvestrant, 25 mg, is **\$78.36**. The \$26.18 copayment shown for HCPCS code J9395, Injection, Fulvestrant, 25 mg, is also incorrect. The **correct copayment** for HCPCS code J9395, Injection, Fulvestrant, 25 mg, is **\$13.09**. The corrected payment rate and copayment have already been installed in the Pricer, and CMS will also address this change in the MedLearn Matters article on CR 3145.

(Source: JSM-189, CI 2370, March 26, 2004)

THIS BULLETIN SHOULD BE SHARED WITH ALL HEALTH CARE PRACTITIONERS AND MANAGERIAL MEMBERS OF THE PROVIDER/SUPPLIER STAFF. ALL BULLETINS ISSUED AFTER OCTOBER 1, 1999 ARE AVAILABLE AT NO COST FROM OUR WEB SITE AT www.marylandmedicare.com.